Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

zzlangerhans (99.67) Submitted: 12/6/2011 11:16:06 PM : Start Price: $7.00 PGNX Score: -15.98

Progenics has jumped nearly 50% in two weeks from their baseline of 5 without a precipitating catalyst, and I smell stirrapulation. The 60M upfront payment from Salix for Relistor was a gift, but that's old news now and the company will surely eat up that cash. Relistor won't be bringing in much revenue even with expanded approval in April 2012, and the PSMA vaccine has been pickling in phase I for at least four years already. At least the company had the good taste to drop their sham virology program.